Todd Smith

Dr. Todd Smith

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
TSTodd Smith
Todd Smith
CGCrystal M. Gigante
Crystal M. Gigante
NWNhien T. Wynn
Nhien T. Wynn
AMAudrey Matheny
Audrey Matheny
WDWhitni Davidson
Whitni Davidson
CHChristina L. Hutson
Christina L. Hutson
Tecovirimat Resistance in Mpox Patients

1 August 2019 in Vaccine
Verified
Journal Article
Closed access
TSTodd Smith
Todd Smith
MMMax Millien
Max Millien
AVAd Vos
Ad Vos
FFFranso A. Fracciterne
Franso A. Fracciterne
KCKelly Crowdis
Kelly Crowdis
RWRyan Wallace
Ryan Wallace

Verified
Journal Article
Open access
PDF file
TSTodd Smith
Todd Smith
AGAmy Gilbert
Amy Gilbert
The rapid fluorescent focus inhibition test (RFFIT) is routinely used in the United States to measure rabies virus neutralizing antibodies (rVNA). RFFIT has a long history of reproducible and reliable results. The test has been modified over the years to use smaller volumes of reagents and samples, but requires a 50 μL minimum volume of test serum. To conduct pathogenesis studies, small laboratory animals such as mice are regularly tested for rVNA, but the minimum volume for a standard RFFIT may be impossible to obtain, particularly in scenarios of repeated sampling. To address this problem, a micro-neutralization test was developed previously. In the current study, the micro-neutralization test was compared to the RFFIT using 129 mouse serum samples from rabies vaccine studies. Using a cut-off value of 0.1 IU/mL, the sensitivity, specificity, and concordance of the micro-neutralization test were 100%, 97.5%, and 98%, respectively. The geometric mean titer of all samples above the cut-off was 2.0 IU/mL using RFFIT and 3.4 IU/mL using the micro-neutralization test, indicating that titers determined using the micro-neutralization test are not equivalent to RFFIT titers. Based on four rVNA-positive hamster serum samples, the intra-assay coefficient of variability was 24% and inter-assay coefficient of variability was 30.4%. These results support continued use of the micro-neutralization test to determine rabies virus neutralizing antibody titers for low-volume serum samples.

Verified
Journal Article
Open access
PDF file
RFRichard Franka
Richard Franka
WCWilliam C. Carson
William C. Carson
JEJames A. Ellison
James A. Ellison
STSteven T. Taylor
Steven T. Taylor
TSTodd Smith
Todd Smith
Charles E. RupprechtCharles E. Rupprecht
Charles E. Rupprecht
Following rabies virus (RABV) exposure, a combination of thorough wound washing, multiple-dose vaccine administration and the local infiltration of rabies immune globulin (RIG) are essential components of modern post-exposure prophylaxis (PEP). Although modern cell-culture-based rabies vaccines are increasingly used in many countries, RIG is much less available. The prohibitive cost of polyclonal serum RIG products has prompted a search for alternatives and design of anti-RABV monoclonal antibodies (MAbs) that can be manufactured on a large scale with a consistent potency and lower production costs. Robust in vitro neutralization activity has been demonstrated for the CL184 MAb cocktail, a 1:1 protein mixture of two human anti-RABV MAbs (CR57/CR4098), against a large panel of RABV isolates. In this study, we used a hamster model to evaluate the efficacy of experimental PEP against a lethal challenge. Various doses of CL184 and commercial rabies vaccine were assessed for the ability to protect against lethal infection with representatives of four distinct bat RABV lineages of public health relevance: silver-haired bat (Ln RABV); western canyon bat (Ph RABV); big brown bat (Ef-w1 RABV) and Mexican free-tailed bat RABV (Tb RABV). 42–100% of animals survived bat RABV infection when CL184 (in combination with the vaccine) was administered. A dose-response relationship was observed with decreasing doses of CL184 resulting in increasing mortality. Importantly, CL184 was highly effective in neutralizing and clearing Ph RABV in vivo, even though CR4098 does not neutralize this virus in vitro. By comparison, 19–95% survivorship was observed if human RIG (20 IU/kg) and vaccine were used following challenge with different bat viruses. Based on our results, CL184 represents an efficacious alternative for RIG. Both large-scale and lower cost production could ensure better availability and affordability of this critical life-saving biologic in rabies enzootic countries and as such, significantly contribute to the reduction of human rabies deaths globally.

1 May 2015 in Vaccine
Verified
Journal Article
Closed access
TSTodd Smith
Todd Smith
MSMarina Siirin
Marina Siirin
XWXianfu Wu
Xianfu Wu
CHCathleen A. Hanlon
Cathleen A. Hanlon
VBVictor Bronshtein
Victor Bronshtein

7 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MEMonir Ejemel
Monir Ejemel
TSTodd Smith
Todd Smith
LGLauren Greenberg
Lauren Greenberg
WCWilliam C. Carson
William C. Carson
DLDavid Lowe
David Lowe
YWYang Wang
Yang Wang
Human rabies remains a globally significant public health problem. Replacement of polyclonal anti-rabies immunoglobulin (RIG), a passive component of rabies post-exposure prophylaxis (PEP), with a monoclonal antibody (MAb), would eliminate the cost and availability constraints associated with RIG. Our team has developed and licensed a human monoclonal antibody RAB1 (Rabishield©), as the replacement for RIG where canine rabies is enzootic. However, for the highly diverse rabies viruses of North America, a cocktail containing two or more MAbs targeting different antigenic sites of the rabies glycoprotein should be included to ensure neutralization of all variants of the virus. In this study, two MAb cocktails, R172 (RAB1-RAB2) and R173 (RAB1-CR57), were identified and evaluated against a broad range of rabies variants from North America. R173 was found to be the most potent cocktail, as it neutralized all the tested North American RABV isolates and demonstrated broad coverage of isolates from both terrestrial and bat species. R173 could be a promising candidate as an alternative or replacement for RIG PEP in North America.